Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 StudyLuis Paz‐Ares, C. Chouaïd, Niels Reinmuth et al.|Journal of Clinical Oncology|2024Cited by 126
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJoseph Gligorov, Luis Matamala, Beyhan Ataseven et al.|European Journal of Cancer|2017Cited by 47